1. The trial is real
Eli Lilly is currently recruiting for RENEW-ALC-1 (NCT07219966), a Phase 3 trial testing an investigational compound called brenipatide against placebo in roughly 1,100 adults with moderate-to-severe alcohol use disorder. Enrollment started in October 2025 and the study runs through April 2028. It's a registered, industry-sponsored trial, nothing speculative about that part.
Brenipatide (development code LY3537031) is Lilly's next dual GLP-1/GIP receptor agonist — the same receptor targets as tirzepatide, the active ingredient in Mounjaro and Zepbound. The distinguishing feature is dosing frequency: where tirzepatide is a weekly injection, brenipatide is engineered for once-monthly subcutaneous dosing via a structural modification that extends its half-life. Lilly is running it across a wide range of indications: Phase 3 for alcohol use disorder and bipolar disorder, Phase 2 for tobacco use disorder, asthma, schizophrenia, and opioid use disorder, and earlier-phase work in cardiovascular and metabolic disease.
2. What is not known yet
- No published efficacy or safety data exists. Everything about how well brenipatide works, in whom, and at what dose is currently based on trial design, not trial results.
- The psychiatric/addiction rationale is mechanistic, not demonstrated in humans. It leans on preclinical work with the related compound tirzepatide showing effects on alcohol-related dopamine signaling in rodent models.
- Specific human dosing has not been disclosed. Phase 2 trials are evaluating multiple dose levels against placebo, but the milligram amounts are not in the public record. Any specific dose figure circulating outside official trial materials is not coming from Lilly.
- There is no approved product and no legitimate supply chain outside the trials themselves. Brenipatide is administered only within Lilly's registered studies.
3. So what's actually being sold as "Brenipatide" online?
Here's the mechanical reason counterfeit versions are already possible: brenipatide's amino acid sequence and CAS number (2408921-49-1) are already public, available through legitimate laboratory reagent catalogs sold for in-vitro reference-standard use. Publishing a sequence doesn't require Lilly's involvement, a completed trial, or regulatory approval — it just requires someone to synthesize it.
That means it's entirely possible for a vial labeled "Brenipatide" to contain a peptide matching the published sequence. It's also entirely possible for it to contain something else — an inactive fragment, a degraded batch, an unrelated compound, or nothing biologically meaningful at all. Without independent, lot-specific analytical verification, there is currently no way to tell the difference from the outside. Critically, there is no established, independent reference standard for the finished investigational drug the way there is for peptides that have been in circulation and independently characterized for years. Any COA attached to a "Brenipatide" listing right now is at best verifying a lab's synthesis against a published sequence — not against Lilly's actual investigational drug product, which has never been characterized publicly.
Worth naming directly: content built around brenipatide is already showing up on peptide-community sites, in some cases running alongside vendor advertising, months before any legitimate supply chain could exist. That's not evidence of fraud on its own, but it's the same pattern that preceded counterfeit tirzepatide and retatrutide vials once those compounds generated public interest ahead of approval — hype outpaces supply, and low-accountability sellers fill the gap.
4. What this means for evaluating a listing
- A drug still in Phase 3 trials has no approved formulation, no established reference standard, and no legitimate consumer supply chain — structurally true regardless of how professional a listing looks.
- A COA is only as good as what it's verified against. For a compound with no independent public reference standard, "purity" and "identity" testing has much less to anchor to than it does for an established research peptide.
- Specific dosing claims are a red flag, not a selling point. Lilly has not published dosing data; a listing or protocol claiming to know the "right" dose is inventing that number.
- Investigational drugs remain investigational for a reason. The entire purpose of the Phase 3 trials enrolling right now is to find out whether the compound is safe and effective at all — that question doesn't have an answer yet, for anyone, at any dose, from any source.
The RENEW-ALC-1 trial itself is a legitimate, transparent, well-documented piece of Lilly's drug development pipeline — exactly the kind of study worth paying attention to. What doesn't hold up is the leap from "this is a real trial" to "therefore this is a real product available outside of it."
Sources
Research-use disclaimer
This article discusses a third-party investigational pharmaceutical compound for informational and educational purposes. It is not a product sold by DAAVY Research, has not been evaluated by the U.S. Food and Drug Administration, and this piece does not encourage seeking out, sourcing, or using it outside of Lilly's registered clinical trials. See our complete research-use policy.